SERBP1 Antibody
Description
What Is a SERBP1 Antibody?
SERBP1 antibodies are immunochemical tools designed to bind specifically to the SERBP1 protein, facilitating its detection in techniques like Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and protein interaction assays. SERBP1 is an RNA-binding protein involved in translation regulation, stress granule dynamics, and cancer progression . Antibodies targeting SERBP1 are critical for studying its expression patterns, subcellular localization, and interactions in physiological and pathological contexts.
Cancer Studies
-
Glioblastoma (GBM): SERBP1 antibodies validated its overexpression in GBM, linking high SERBP1 levels to poor patient survival and therapy resistance. Knockdown experiments using antibodies confirmed SERBP1’s role in methionine metabolism and histone methylation .
-
Ovarian Cancer: Antibodies identified SERBP1 as a prognostic marker, with overexpression correlating with tumor grade and metastasis .
Neurodegenerative Diseases
-
Alzheimer’s Disease (AD): SERBP1 antibodies revealed its co-localization with hyperphosphorylated Tau aggregates in AD brains. Western blot analyses showed increased SERBP1 expression in AD compared to controls .
Stress Granule Dynamics
-
Germ Cell Stress Response: Antibodies demonstrated SERBP1’s recruitment into stress granules (SGs) in mouse testes under arsenite stress. SERBP1 knockdown via shRNA increased germ cell apoptosis, highlighting its protective role in stress adaptation .
Key Research Findings Enabled by SERBP1 Antibodies
Protocols and Technical Considerations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
SERBP1 Gene References and Functions
- Studies suggest that the miR-218/SERBP1 signaling pathway can inhibit the development of malignant phenotypes, indicating its potential as a therapeutic target for hepatocellular carcinoma (HCC). PMID: 28369267
- Research demonstrates that SERBP1 has been identified as a downstream target of microRNA miR-26a-5p. PMID: 27449037
- SERBP1 is a constituent of the LRH-1 transcriptional complex. PMID: 26398198
- Higher levels of PAI-RBP1 expression have been observed in non-small cell lung cancer tissues compared to normal tissues. PMID: 22373659
- Pseudomyogenic haemangioendothelioma consistently exhibits a SERPINE1-FOSB fusion gene, resulting from a translocation between chromosomes 7 and 19. PMID: 24374978
- The RNA-binding protein SERBP1 is highly expressed in human breast cancer, potentially serving as a novel breast tumor marker with prognostic significance. PMID: 23236990
- The RG-rich and RGG box of SERBP1 undergoes asymmetrical dimethylation by PRMT1, influencing protein interactions and its intracellular localization. PMID: 22442049
- The 4G allele of the 4G/5G polymorphism in the PAI-1 gene may contribute to the risk of IgE-mediated asthma and allergic diseases. PMID: 11972486
- While the PAI-1 gene promoter polymorphism does not influence the development of abdominal aortic aneurysms (AAA), the 5G5G genotype appears to provide protection against mortality following open aneurysm repair. PMID: 12027469
- Observations indicate that CGI-55 localizes to the nucleolus and co-localizes with p80-coilin positive nuclear-coiled bodies. PMID: 16679534
- SERBP1 possesses two conserved Gly/Arg-rich motif clusters (RGG/RXR box, where X represents any amino acid), which may serve as substrates for arginine-methylation by protein arginine-methyltransferase-1 (PRMT1). PMID: 16879614
- The presence of genotype risk factors alone does not appear to be associated with the development of preeclampsia, even in severe forms. However, PAI-1 gene polymorphisms have been implicated in the development of preeclampsia. PMID: 16963292
- In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a role in tumor invasion and metastasis. Its expression is elevated in advanced disease stages. PMID: 17698176
- This gene encodes the protein PAI-RBP1, which binds to an RNA sequence (cyclic nucleotide responsive sequence, CRS) within the plasminogen activator-inhibitor (PAI-1) mRNA. This binding confers cAMP regulation of mRNA stability. PMID: 11001948
Q&A
Basic Research Questions
How to validate SERBP1 antibody specificity across experimental applications?
Validation requires a multi-step approach:
-
Peptide competition assays: Pre-incubate the antibody with its immunogen peptide (e.g., sequence CKKEGIRRVGRR) to confirm signal loss in Western blot (WB) or IHC .
-
Knockdown/knockout controls: Use shRNA-mediated SERBP1 depletion (e.g., shSERBP1 THP1 cells) to demonstrate reduced signal intensity in WB .
-
Cross-reactivity checks: Test lysates from tissues with low endogenous SERBP1 (e.g., normal brain) versus high-expression tissues (e.g., glioblastoma) .
What protocols optimize SERBP1 detection in immunohistochemistry?
How to troubleshoot high background in immunofluorescence?
-
Reduce non-specific binding: Use 0.1% Triton X-100 for permeabilization and include isotype-matched IgG controls .
-
Optimize fixation: Paraformaldehyde (4%) preserves SERBP1 localization in stress granules, while methanol fixation may disrupt epitopes .
Advanced Research Questions
How to resolve molecular weight discrepancies (45 kDa predicted vs 55 kDa observed)?
SERBP1 migrates anomalously at ~55 kDa due to:
-
Post-translational modifications: Phosphorylation or arginine methylation in its RG/RGG domains .
-
Dimerization: Non-reducing conditions may preserve dimeric forms, as observed in Alzheimer’s brain lysates .
Validate using denaturing SDS-PAGE with fresh β-mercaptoethanol and compare with recombinant SERBP1 standards .
What controls are essential for studying SERBP1 in neurodegenerative aggregates?
-
Disease-specific controls: Compare Alzheimer’s (AD) brain tissues with age-matched controls to assess SERBP1 accumulation in Tau aggregates .
-
Co-staining markers: Use G3BP1 (stress granule marker) or PARP1 (PARylation) to confirm SERBP1’s role in pathological condensates .
-
Proximity ligation assays (PLA): Quantify SERBP1 interactions with hyperphosphorylated Tau using PLA signals normalized to negative controls .
How does SERBP1 expression vary between latent and lytic viral infections?
How to interpret context-dependent SERBP1 roles in cancer vs neurodegeneration?
-
Cancer: High SERBP1 correlates with poor prognosis in breast/lung tumors. Use IHC on FFPE sections with antigen retrieval optimized for tumor microenvironments .
-
Neurodegeneration: In AD, prioritize co-immunoprecipitation with FMRP/FXR1 to study synaptic translation defects .
Contradictions arise from tissue-specific interactors (e.g., PARP1 in AD vs CHD3/KAP1 in viral latency) .
What orthogonal methods confirm SERBP1-RNA interactions in gene regulation?
-
RNA immunoprecipitation (RIP): Crosslink with formaldehyde and validate bound RNAs (e.g., snoRNAs in Tau aggregates) via qPCR .
-
In situ hybridization: Pair with SERBP1 IF to localize mRNA-protein complexes (e.g., SERPINE1 mRNA in stress granules) .
Methodological Best Practices
-
Antibody lot validation: Compare new lots with published data (e.g., Proteintech 10729-1-AP validation in mouse testis) .
-
Quantitative normalization: Use β-actin or GAPDH for WB, but avoid these in neuronal studies due to variable expression in AD .
-
Data contradiction analysis: If conflicting results arise (e.g., dimerization vs monomeric forms), re-analyze under non-reducing vs reducing conditions .
